Chipotle 2013 Annual Report Download - page 83

Download and view the complete annual report

Please find page 83 of the 2013 Chipotle annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

Class II directors whose terms expire at
the 2016 annual meeting of shareholders Age
Director
Since
Neil W. Flanzraich .............. Mr.Flanzraich has been a private investor since February
2006. He is also the Chairman and CEO of Cantex
Pharmaceuticals, Inc. (formerly ParinGenix, Inc.), a
privately-owned biotech company. From 1998 through its
sale in January 2006 to TEVA Pharmaceuticals
Industries, Ltd., he served as Vice Chairman and
President of IVAX Corporation, an international
pharmaceutical company. From 1995 to 1998,
Mr. Flanzraich served as Chairman of the Life Sciences
Legal Practice Group of Heller Ehrman LLP, a law firm,
and from 1981 to 1994, served as the Senior Vice
President and Chief Counsel and member of the
Operating and Executive Committees of Syntex
Corporation, an international pharmaceutical company.
Mr. Flanzraich’s executive experience has helped him
develop outstanding skills in leading and managing strong
teams of employees, and in oversight of the growth and
financing of businesses in a rapidly-evolving market. His
legal background also is valuable to us in the risk
management area, and Mr. Flanzraich brings to us
extensive experience serving as an independent director
of other public and privately-held companies. He is a
director of Equity One Inc. (NYSE:EQY). Mr. Flanzraich
was a director of BELLUS Health Inc. until May 2012, a
director of Continucare Corporation until October 2011, a
director of Javelin Pharmaceuticals, Inc. until July 2010,
and a director of RAE Systems, Inc. until March 2009.
Mr. Flanzraich received an A.B. from Harvard College
and a J.D. from Harvard Law School.
70 2007
Darlene J. Friedman ............. Prior to retiring in 1995, Ms. Friedman spent 19 years at
Syntex Corporation, a pharmaceutical company, where
she held a variety of management positions, most recently
as Senior Vice President of Human Resources. While at
Syntex, Ms. Friedman was a member of the corporate
executive committee and the management committee, and
was responsible for the analysis, recommendation and
administration of the company’s executive compensation
programs and worked directly with the compensation
committee of Syntex’s board. This experience and
Ms. Friedman’s talent in these areas are invaluable in
connection with her service as a director and as a member
of our Compensation Committee. Ms. Friedman holds a
Bachelor of Arts degree in psychology from the
University of California at Berkeley and an MBA from
the University of Colorado.
71 1995
The Board of Directors held four meetings in 2013 and acted by written consent two times. Each director
who served as a director for the full year attended at least 75 percent of the meetings of the Board and of
committees of which they were members during 2013. Mr. Musk attended each meeting of the Board in 2013
from and after the date of his appointment to the Board. The Board has requested that each member attend our
11
Proxy Statement